RT Journal Article
SR Electronic
T1 Sixty-day mortality among 520 Italian hospitalized COVID-19 patients according to the adopted ventilatory strategy in the context of an integrated multidisciplinary clinical organization: a population-based cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.13.20174615
DO 10.1101/2020.08.13.20174615
A1 Potalivo, Antonella
A1 Montomoli, Jonathan
A1 Facondini, Francesca
A1 Sanson, Gianfranco
A1 Agli, Luigi Arcangelo Lazzari
A1 Perin, Tiziana
A1 Cristini, Francesco
A1 Cavagna, Enrico
A1 Giovanni, Raffaella De
A1 Biagetti, Carlo
A1 Panzini, Ilaria
A1 Ravaioli, Cinzia
A1 Bitondo, Maddalena
A1 Guerra, Daniela
A1 Giuliani, Giovanni
A1 Mosconi, Elena
A1 Guarino, Sonia
A1 Marchionni, Elisa
A1 Gangitano, Gianfilippo
A1 Valentini, Ilaria
A1 Giampaolo, Luca
A1 Muratori, Francesco
A1 Nardi, Giuseppe
YR 2020
UL http://medrxiv.org/content/early/2020/08/15/2020.08.13.20174615.abstract
AB Background Among COVID-19 patients, the decision of which ventilation strategy to adopt is crucial and not guided by existing outcome evidence. We described the clinical characteristics and outcomes of hospitalized COVID-19 patients according to the adopted respiratory strategy.Methods Population-based cohort study including all COVID-19 patients (26/02/2020-18/04/2020) within Rimini Italian province. Hospitalized patients were classified according to the maximum level of respiratory support: oxygen supplementation (group Oxygen), NIV (group NIV-only), IMV (group IMV-only), and IMV after a NIV trial (group IMV-after-NIV). Sixty-day mortality risk was estimated with a Cox proportional hazard analysis adjusted by age, sex, and administration of steroids, canakinumab, and tocilizumab.Findings We identified 1,424 symptomatic patients: 520 (36.5%) were hospitalized, the remaining 904 (63.5%) were treated at home with no 60-days death. According to the respiratory support, 408 (78.5%) were assigned to Oxygen, 46 (8.8%) to NIV-only, 25 (4.8%) to IMV-after-NIV, and 41 (7.9%) to IMV-only groups. There was no significant difference in the P/F at IMV inception among IMV-after-NIV and IMV-only groups (p=0.9). Overall 60-day mortality was 24.2% (Oxygen: 23.0%; NIV-only: 19.6%; IMV-after-NIV: 32.0%; IMV-only: 36.6%; p = 0.165). Compared with Oxygen group, the 60-day mortality risk significantly increased for IMV-after-NIV (HR 2.776; p=0.024) and IMV-only group (HR 2.966; p=0.001).Conclusions This study provides a population-based figure of the impact of the COVID-19 epidemic. A similar 60-days mortality risk was found for patients undergoing immediate IMV and those intubated after a NIV trial. Many patients had a favorable outcome after prolonged IMV.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study has not been registered since it is an observational historical studyFunding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The investigation conforms with the principles outlined in the Declaration of Helsinki. The AUSL della Romagna Institutional Review Board approved the project (registration number NCT04348448) with a waiver of informed consent. No additional procedure or investigation potentially related to the study was requested or provided.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected for the study appropriately deidentified, will be made available to others upon an official proposal describing the rationale and the statistical analysis plan intended to be performed by the proponent institution. A signed data access agreement will be required for handling the data.